Condition
Complications of Diabetes Mellitus
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 9 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
9 shownThe Relationship Between Intraocular Pressure and Macular Edema in Patients With Diabetic Macular EdemaNCT02718547 · 2017-03-26
UNKNOWNClinical Observation of Coronary Arterial Microcirculation Dysfunction in Diabetic Patients With Non- Obstructive Coronary Artery DiseaseNCT02748980 · 2016-03-01
UNKNOWNED Management of Severe Hyperglycemia: A Clinical TrialNCT02478190 · 2015-06-01
COMPLETED18F-Sodium Fluoride (18F-NaF) PET-CT Imaging to Identify Vulnerable Plaques in Patients With DiabetesNCT03530176 · 2015-01-01
COMPLETEDCharacterization of the Charcot FootNCT02335931 · 2014-09-01
COMPLETEDTechnological Rehabilitation of Distal Sensorimotor Polyneuropathy in Diabetic PatientsNCT01926522 · 2013-09-01
COMPLETEDClinical Study on Metabolic Surgery Compared to the Best Clinical Treatment in Patients With Type 2 Diabetes MellitusNCT01821508 · 2013-04-18
COMPLETEDEffect of Diacerein in the Metabolic Control of Patients With DM Type 2 and Secondary Failure to MetforminNCT03208309 · 2013-01-01
COMPLETEDAcute Changes in Intraocular Cytokines After Intravitreal BevacizumabNCT01439178 · 2011-08-01
UNKNOWNCommon interventions
18Fluoride-Sodium Fluoride radio-isotopeRADIATION1Clinical TreatmentOTHER1CombiganDRUG1Control RehabilitationOTHER1DiacereinDRUG1Intravitreal Avastin injectionDRUG1Loose control: goal glucose 600 mg/dL or lowerOTHER1PlaceboDRUG1Roux-En-Y gastric bypass surgeryPROCEDURE1Technological RehabilitationDEVICE1Tight control: goal glucose 350 mg/dL or lowerOTHER1
Leading sponsors
Trial status mix
COMPLETED6
UNKNOWN3
Phase mix
NA6
PHASE21
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.